The major brain endocannabinoid 2-AG controls neuropathic pain and mechanical hyperalgesia in patients with neuromyelitis optica.
Recurrent myelitis is one of the predominant characteristics in patients with neuromyelitis optica (NMO). While paresis, visual loss, sensory deficits, and bladder dysfunction are well known symptoms in NMO patients, pain has been recognized only recently as another key symptom of the disease. Although spinal cord inflammation is a defining aspect of neuromyelitis, there is an almost complete lack of data on altered somatosensory function, including pain. Therefore, eleven consecutive patients with NMO were investigated regarding the presence and clinical characteristics of pain. All patients were examined clinically as well as by Quantitative Sensory Testing (QST) following the protocol of the German Research Network on Neuropathic Pain (DFNS). Additionally, plasma endocannabinoid levels and signs of chronic stress and depression were determined. Almost all patients (10/11) suffered from NMO-associated neuropathic pain for the last three months, and 8 out of 11 patients indicated relevant pain at the time of examination. Symptoms of neuropathic pain were reported in the vast majority of patients with NMO. Psychological testing revealed signs of marked depression. Compared to age and gender-matched healthy controls, QST revealed pronounced mechanical and thermal sensory loss, strongly correlated to ongoing pain suggesting the presence of deafferentation-induced neuropathic pain. Thermal hyperalgesia correlated to MRI-verified signs of spinal cord lesion. Heat hyperalgesia was highly correlated to the time since last relapse of NMO. Patients with NMO exhibited significant mechanical and thermal dysesthesia, namely dynamic mechanical allodynia and paradoxical heat sensation. Moreover, they presented frequently with either abnormal mechanical hypoalgesia or hyperalgesia, which depended significantly on plasma levels of the endogenous cannabinoid 2-arachidonoylglycerole (2-AG). These data emphasize the high prevalence of neuropathic pain and hyperalgesia in patients with NMO. The degree of mechanical hyperalgesia reflecting central sensitization of nociceptive pathways seems to be controlled by the major brain endocannabinoid 2-AG.
Institute for Clinical Neuroimmunology, Ludwig-Maximilians University, Munich, Germany.
Hannah L
HL
Pellkofer
Joachim
J
Havla
Daniela
D
Hauer
Gustav
G
Schelling
Shahnaz C
SC
Azad
Tania
T
Kuempfel
Walter
W
Magerl
Volker
V
Huge
D000328:Adult; D000368:Aged; D001095:Arachidonic Acids / Q000097:blood*; D001921:Brain / Q000378:metabolism* / Q000503:physiopathology; D016022:Case-Control Studies; D003863:Depression / Q000097:blood / Q000150:complications / Q000503:physiopathology*; D063388:Endocannabinoids / Q000097:blood*; D005260:Female; D005989:Glycerides / Q000097:blood*; D006801:Humans; D006930:Hyperalgesia / Q000097:blood / Q000503:physiopathology*; D006987:Hypesthesia / Q000097:blood / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009437:Neuralgia / Q000097:blood / Q000503:physiopathology*; D009471:Neuromyelitis Optica / Q000097:blood / Q000150:complications / Q000503:physiopathology*; D009900:Optic Nerve / Q000378:metabolism / Q000503:physiopathology; D010147:Pain Measurement; D017288:Pain Threshold; D011581:Psychological Tests; D013116:Spinal Cord / Q000378:metabolism / Q000503:physiopathology
D001095:Arachidonic Acids; D063388:Endocannabinoids; D005989:Glycerides; C094503:glyceryl 2-arachidonate